BioCentury | Feb 14, 2020
Targets & Mechanisms

Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors

Rising serial entrepreneur Akiko Iwasaki aims to bring antitumor immunity to the brain by opening the brain’s lymphatics, a recently discovered system of vessels just starting to find translational uses. In 2015, a Nature paper...
BioCentury | Jan 30, 2020
Distillery Therapeutics

IL1RL1 in Treg cells as a lung cancer target

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Inhibiting IL1RL1, which signals in response to IL-33 binding, in Treg cells could treat lung cancer. In single-cell RNA sequencing analyses of CD4 + T cells from the lymph...
BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

Arguably, the most important innovations on the horizon for Type I diabetes would replace the insulin-producing cells patients have lost or prevent at-risk individuals from losing the cells in the first place. With Provention planning...
BioCentury | Jan 14, 2020
Emerging Company Profile

Kyverna applies Tregs, CAR Ts to autoimmune diseases with $25M series A, Gilead deal

The team behind Cell Design Labs and its acquirers at Gilead are looking to capitalize on their T cell engineering platform again, bringing it into new indications with the launch of Kyverna. The company is...
BC Innovations | Dec 20, 2019
Targets & Mechanisms

Controlling T cells via epigenetics

An international academic team has discovered an epigenetic pathway that regulates CD4 + T cell differentiation and activity, and could yield new therapeutic targets for autoimmunity. As drug developers seek the next generation of targeted...
BC Innovations | Dec 19, 2019
Distillery Therapeutics

SLC5A12 inhibition for rheumatoid arthritis

DISEASE CATEGORY: Autoimmune disease INDICATION: Rheumatoid arthritis (RA) Inhibiting the lactate transporter SLC5A12 could treat RA. In 87 patients with early RA, high levels of SLC5A12 RNA expression in the synovium was associated with increased...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BioCentury | Nov 23, 2019
Product Development

Sanofi adds in home-grown trispecific antibody technology to grow oncology franchise

Promising preclinical data from a trispecific mAb platform developed by Sanofi could provide a new growth platform for its cancer pipeline, as the pharma seeks to wean off its reliance on Regeneron. Sanofi (Euronext:SAN; NYSE:SNY)...
BC Extra | Nov 23, 2019
Company News

Nov. 22 Company Quick Takes: AZ’s Btk inhibitor gains expanded approval; plus WuXi Vaccines, SK Bio, ViiV, Horizon and Neon

Label expansion for AZ’s Calquence under Project ORBIS  FDA approved an sNDA for Calquence acalabrutinib from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat chronic lymphocytic leukemia and small lymphocytic leukemia under the agency’s Real-Time Oncology Review...
BC Extra | Oct 29, 2019
Clinical News

GSK vaccine could provide alternative for TB

In line with two-year data, GSK reported that its pulmonary tuberculosis vaccine lowered the incidence of active disease by 50% at three years. M72/AS01E could provide an alternative to the only approved TB vaccine, Bacillus...
Items per page:
1 - 10 of 1494